Decline in Birth Rates: China's births in 2025 fell to 7.92 million, a 17% decrease from 2024, which was below expectations and may negatively impact infant formula stocks.
Government Measures: Despite various government initiatives to encourage childbirth, including extended parental leave and relaxed marriage registration, the low birth rate continues to be a significant issue.
Demographic Challenges: The declining birth rate presents serious demographic challenges for China, prompting speculation that the government may introduce additional incentives to promote marriages and births.
Stock Ratings: A report from Citi Research includes ratings and target prices for infant formula stocks, indicating a mixed outlook for companies in this sector amidst the declining birth rates.
Wall Street analysts forecast 01112 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01112 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 01112 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 01112 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 14.020
Low
Averages
High
Current: 14.020
Low
Averages
High
Citi
Citi Research
Neutral
maintain
$4.3
2026-01-20
New
Reason
Citi
Citi Research
Price Target
$4.3
AI Analysis
2026-01-20
New
maintain
Neutral
Reason
The analyst rating from Citi Research is influenced by the significant decline in China's birth rate, which fell to 7.92 million in 2025, a 17% year-over-year drop. This figure was below expectations and is expected to create headwinds for infant formula stocks. Despite government efforts to encourage childbirth through various measures, the low birth rate continues to pose demographic challenges, leading to cautious outlooks on the infant formula market. Consequently, the ratings reflect a "Neutral" stance on CHINA FEIHE and a "Buy" recommendation for H&H INTL HLDG, indicating differing levels of confidence in their performance amidst these challenges.
Haitong International
Outperform
initiated
$17
2025-12-22
Reason
Haitong International
Price Target
$17
2025-12-22
initiated
Outperform
Reason
Haitong International has given H&H INTL HLDG an Outperform rating and a target price of HKD17 based on their projections of significant net profit growth over the next few years. They estimate net profits to reach RMB415 million in 2025, RMB641 million in 2026, and RMB818 million in 2027, which translates to year-over-year growth rates of 873.36%, 54.35%, and 27.50%, respectively. Additionally, they forecast earnings per share (EPS) to increase to RMB0.64, RMB0.99, and RMB1.27 during the same period. This strong growth outlook is the primary reason for the positive analyst rating.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for 01112
Unlock Now
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
